Aktis Oncology, Inc. (AKTS) — Financial ratios
Profitability, liquidity, leverage, and valuation ratios for Aktis Oncology, Inc., with annual and quarterly history.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Valuation | ||||
| P/E Ratio | -18.46x | -17.76x | -27.27x | -43.56x |
| P/B Ratio | -8.05x | -8.89x | -16.87x | -40.61x |
| P/S Ratio | 181.08x | 525.20x | 0.00x | 0.00x |
| Profitability | ||||
| Gross Margin | 100.0% | 100.0% | 0.0% | 0.0% |
| Operating Margin | -1149.5% | -3500.3% | 0.0% | 0.0% |
| Net Margin | -980.9% | -2957.6% | 0.0% | 0.0% |
| EBITDA Margin | -1113.7% | -3394.4% | 0.0% | 0.0% |
| Liquidity | ||||
| Current Ratio | 7.37x | 15.98x | 16.07x | 25.11x |
| Quick Ratio | 7.37x | 15.98x | 16.07x | 25.11x |
| Leverage | ||||
| Debt/Equity | -0.08x | -0.14x | -0.29x | -0.09x |
YoY = year-over-year change. Source: FMP..